Curis, Inc. (NASDAQ:CRIS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
(b) On October5, 2017, Kenneth J. Pienta, M.D. notified the Board of Directors of Curis, Inc. (the “Company”), that, effective immediately, he will resign as a member of the Board of Directors to pursue other opportunities, including in the biotechnology industry. The Board and the management team join together in thanking Dr.Pienta for his services as a member of the Board of Directors, and wish him well in all of his endeavors.
About Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.
